In short
This article discusses ongoing clinical trials investigating the use of BT5528, a novel drug containing Monomethyl Auristatin E linked to a sarcosine decamer with a beta-alanine N-terminus and BCY9594 via a cleavable linker. The trials aim to evaluate the safety, effectiveness, and potential benefits of BT5528 in treating advanced solid tumors that express the EphA2 protein. The study includes both monotherapy and combination therapy with nivolumab, focusing on various cancer types such as urothelial, ovarian, lung, head and neck, breast, and gastrointestinal cancers.
At a glance
- Drug Name
- BT5528 (Monomethyl Auristatin E linked to a sarcosine decamer with a beta-alanine N-terminus and BCY9594 via a cleavable linker)
- Trial Phase
- Phase I/II integrated trial
- Target Conditions
- Advanced solid tumors expressing EphA2, including urothelial, ovarian, lung, head and neck, breast, and gastrointestinal cancers
- Main Objectives
- Assess safety, tolerability, determine MTD and RP2D, evaluate preliminary clinical activity
- Treatment Approaches
- BT5528 monotherapy and in combination with nivolumab
- Key Endpoints
- Treatment-emergent adverse events, dose-limiting toxicities, objective response rate, duration of response, progression-free survival, overall survival
- Eligibility Criteria
- Adults with advanced solid tumors, measurable disease, adequate organ function, available tumor tissue for analysis
- Additional Assessments
- Pharmacokinetics of BT5528 and MMAE, anti-drug antibody development
What is BT5528?
BT5528 is an innovative drug being developed to treat advanced solid tumors that express a protein called EphA2. It's also known by other names such as BCY6136. The drug is made up of a powerful anti-cancer component called monomethyl auristatin E (MMAE) connected to a targeting molecule via a special link.
How Does BT5528 Work?
BT5528 works like a smart missile for cancer cells. The targeting part of the drug (BCY9594) helps it find cancer cells that have a lot of EphA2 protein on their surface. Once it reaches these cells, the link breaks, releasing the MMAE, which can then kill the cancer cells. This targeted approach aims to attack cancer cells while minimizing damage to healthy cells.
What Conditions Does BT5528 Target?
BT5528 is being studied for treating various types of advanced solid tumors that express EphA2. These may include:
- Urothelial cancer (cancer of the bladder lining)
- Ovarian cancer
- Non-small cell lung cancer (NSCLC)
- Head and neck cancer
- Triple negative breast cancer (TNBC)
- Gastric/upper gastrointestinal cancer
These types of cancers are known to often have high levels of EphA2 protein, making them potential targets for BT5528.
Current Clinical Trial
BT5528 is currently being studied in a Phase I/II clinical trial. This trial aims to:
- Assess the safety and tolerability of BT5528
- Determine the right dose for future studies
- Look for early signs that the drug is working against tumors
- Study how the drug moves through and is processed by the body (pharmacokinetics)
The trial is divided into different parts: Part A-1: Testing BT5528 alone Part A-2: Testing BT5528 in combination with another immunotherapy drug called nivolumab Part B: Further testing BT5528 alone in specific cancer types
Who Can Participate in the Trial?
The trial has specific criteria for who can participate. In general, patients must:
- Be at least 18 years old
- Have advanced solid tumors that express EphA2
- Have measurable disease
- Have adequate organ function
- Not have certain other health conditions that might interfere with the study
It's important to note that there are additional specific criteria, and only a healthcare provider can determine if someone is eligible for the trial.
Potential Benefits and Risks
While BT5528 shows promise, it's important to remember that it's still in the testing phase. Potential benefits may include shrinking tumors or slowing cancer growth, but these are not guaranteed.
As with any experimental treatment, there may be risks and side effects. The trial is designed to carefully monitor patients for any adverse effects. Some areas of particular concern include:
- Effects on blood cells
- Liver function
- Heart rhythm
- Potential for increased risk of bleeding or blood clots
Patients considering participating in this trial should discuss the potential risks and benefits thoroughly with their healthcare provider.